Compare · AGL vs FMS
AGL vs FMS
Side-by-side comparison of agilon health inc. (AGL) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.36B, about 8.3x AGL ($1.49B).
- FMS has been more active in the news (5 items in the past 4 weeks vs 3 for AGL).
- AGL has more recent analyst coverage (25 ratings vs 24 for FMS).
- Company
- agilon health inc.
- Fresenius Medical Care AG
- Price
- -
- -
- Market cap
- $1.49B
- $12.36B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 5
- Recent ratings
- 25
- 24
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest AGL
- agilon health Sets Date to Report Third Quarter 2026 Financial Results
- agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO
- agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO
- agilon health upgraded by Bernstein with a new price target
- agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO
- agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference
- agilon health to Participate in Upcoming Conferences
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 17 shares, decreasing direct ownership by 0.12% to 14,152 units (SEC Form 4) (withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth
- Fresenius Medical downgraded by Berenberg
- Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care Announces Publication of a Multinational Real-World Evidence Study Associating High-Volume Hemodiafiltration with Lower Mortality Risk Than Conventional Hemodialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG